The companies in question, Dr. Reddy’s Laboratories, Sun Pharma and Zydus Pharmaceuticals, are recalling seizure treatments, ...

Common chemotherapy drugs such as vincristine (Sh300 per vial), cyclophosphamide (Sh350 per vial), cisplatin (Sh700), doxorubicin (Sh900), and cytarabine (Sh400) have remained relatively stable in ...

Heron Therapeutics' market cap has risen to ~$360 million, trading at ~$2.38, since my last Hold rating in November 2024.

A key clinical trial found that adding blinatumomab to consolidation chemotherapy in MRD-negative ... on the list price of £2,017 per 38.5-μg vial. The drug was approved in the United States ...

"The chemotherapy had already left me with little ... I had my own blood cells removed, modified, and reinfused in two vials. "Four weeks in hospital, and then I was sent home.

Fennec Pharmaceuticals Inc. (NASDAQ: FENC) Q4 2024 Earnings Call Transcript March 10, 2025 Fennec Pharmaceuticals Inc. misses ...

Good morning ladies and gentlemen, and welcome to Fennec Pharmaceuticals fourth quarter and full year 2024 earnings and corporate update conference call. (Operator Instructions) As a reminder, today's ...

Q4 2024 Earnings Call Transcript March 3, 2025 Operator: Good day, everyone, and welcome to the Syndax Fourth Quarter and Full Year 2024 Earnings Conference Call. Today’s call is being recorded.

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced certain operational results following approval of the permanent J-code ...

In mid-January, we and our commercialization partner Incyte announced that the FDA approved Niktimvo in 9 milligram and 22 milligram vial sizes ... unfit for intensive chemotherapy, as well ...

Celltrion today announced the U.S. launch of STEQEYMA��(ustekinumab-stba), a biosimilar to STELARA� (ustekinumab), following approval by the U.S. Food and Drug Administration (FDA) in December 2024.